MRVI

Maravai LifeSciences Holdings, Inc. stock has experienced several notable events in the past six months. The stock price increased by 49.2% from January 1st, 2026, to May 9th, 2026, trading at $4.85. Over the past year, the stock is up 26% and has reached a new 1-year high. Maravai reported strong first-quarter results, with total revenue up 41% year-over-year to $65.8 million, beating consensus estimates. Following the strong Q1 performance, Maravai raised its full-year 2026 revenue guidance to a range of $205.0 million to $215.0 million and adjusted EBITDA guidance to $30.0 million to $32.0 million. The company's stock reached a new 1-year high following an analyst upgrade. Maravai LifeSciences Holdings, Inc. reported a goodwill impairment of $11,912,000 for the fourth quarter ended December 31, 2024.